Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Climb Bio ( (CLYM) ) has shared an announcement.
Climb Bio, Inc. announced on October 17, 2025, the publication of new long-term follow-up clinical data for budoprutug, a novel anti-CD19 monoclonal antibody in development for B-cell mediated diseases. The data from a Phase 1b clinical trial showed that budoprutug provided long-term control of proteinuria in primary membranous nephropathy patients for up to three years, with no need for further immunosuppressive treatment in most cases and no severe treatment-related adverse events observed.
The most recent analyst rating on (CLYM) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.
Spark’s Take on CLYM Stock
According to Spark, TipRanks’ AI Analyst, CLYM is a Neutral.
Climb Bio’s stock score is primarily driven by its financial performance, reflecting the company’s developmental challenges with negative income and cash flow. Despite strong equity and cash reserves, the technical indicators show a bearish trend, and the valuation reflects typical early-stage biotech characteristics with a negative P/E ratio. The absence of significant earnings call data or corporate events means the focus remains on financial stability and potential for future growth.
To see Spark’s full report on CLYM stock, click here.
More about Climb Bio
Average Trading Volume: 669,884
Technical Sentiment Signal: Sell
Current Market Cap: $132.1M
For detailed information about CLYM stock, go to TipRanks’ Stock Analysis page.